Clinical usefulness of measuring the number of Circulating Tumor Cells (CTC) in breast cancer patients
Journal Title: OncoReview - Year 2013, Vol 3, Issue 3
Abstract
Background: Monitoring the breast cancer patients after an adjuvant therapy usually involves imaging methods or biopsy. Alternatively, breast cancer markers can be determined – one of them is the number of circulating tumor cells (CTC).Aim: The aim of this study was to compare the efficacy of standard monitoring methods and those based on CTC count.Materials and methods: Systematic review of PubMed database was performed. Inclusion criteria were met by 16 clinical trials, 9 reviews and 5 treatment recommendations.Results: CTC assay sensitivity was between 39% and 55% compared to the imaging, and 64% in combination with CA 27.29 (cancer antigen 27.29) marker. CTC specificity for the detection level of < 5 or ≥ 5 CTCs in blood was almost 100%. CTC assay enables correct classification of patients according to the neoplastic disease progression. Overall survival (OS) and progression free survival (PFS) were correlated with blood CTCs in metastatic patients. The study results suggest a link between CTC level and imaging diagnosis. Patients with CTC ≥ 5 were at a higher risk of disease progression, as diagnosed by radiographic methods, than patients with CTC < 5.Conclusions: Blood CTC measurement is a good clinical predictor of overall survival and progression-free survival and can be used for treatment efficacy monitoring in patients at high risk of recurrence or progression during advanced breast cancer treatment.
Authors and Affiliations
Dariusz Brenski
Keywords
Related Articles
- EP ID EP67724
- DOI -
- Views 217
- Downloads 0
Pericardiocentesis and pericardial therapy aspects in cancer patients - a case report
The malignancy related pericardial effusion has variable dynamics, and the clinical presentation and severity of symptoms are directly related to the degree of hemodynamic conditions and the rate of fluid accumulation in...
Cardiooncological balance in a 75-year-old male with a hepatocellular carcinoma CS IV and a congestive heart failure NYHA III „de novo”
The case reports about a 75-years-old man without a previous medical history, in whom a heart failure NYHA III de novo was diagnosed together with persistent atrial fibrillation and hepatocellular carcinoma in clinical s...
Everolimus-induced interstitial lung disease in patient with metastatic renal cell carcinoma – case report and literature review
We present a case of a 70-year-old man with metastatic renal cell carcinoma treated with second-line everolimus after rapid progression on first-line tyrosine kinase inhibitor, in whom a side effect of the therapy occurr...
Bezpieczeństwo kardiologiczne podczas stosowania sunitinibu i sorafenibu, wielokinazowych inhibitorów angiogenezy
Kardiotoksyczność wielokinazowych inhibitorów angiogenezy, sunitinibu i sorafenibu, objawia się najczęściej w postaci dysfunkcji skurczowej mięśnia sercowego oraz tętniczych i żylnych zdarzeń zakrzepowo-zatorowych. Istot...
Childhood Cancer Survivorship Late Cardiotoxicity, and CV Prevention